Ciltacabtagene Autoleucel
Institute issues draft scoping plan for review of anti-BCMA therapies for multiple myeloma
The Institute for Clinical and Economic Review has completed a draft scoping document for its planned assessment of chimeric antigen receptor T-cell therapies for the treatment of multiple myeloma.
VIDEO: Similarities, differences between CAR T-cell therapies for multiple myeloma
In this video, Saad Usmani, MD, a myeloma specialist at Memorial Sloan Kettering Cancer Center, discusses the treatment outlook for CAR T-cell patients in multiple myeloma.
VIDEO: Addressing manufacturing, production time challenges of CAR T-cell therapy
In this video, Saad Usmani, MD, a myeloma specialist at the Memorial Sloan Kettering Cancer Center, discusses early challenges with CAR T-cell therapy in multiple myeloma and how doctors and researchers have approached and overcome them in recent years.
VIDEO: CAR T-cell therapies for multiple myeloma ‘have come a long way'
In this video, Saad Usmani, MD, a myeloma specialist at the Sloan Kettering Memorial Cancer Center, discusses the latest advancements in CAR T-cell therapy in multiple myeloma, including the major progress the therapy has made over the last few years.